Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EBT (2016 - 2025)

KalVista Pharmaceuticals' EBT history spans 11 years, with the latest figure at $38.6 million for Q2 2025.

  • On a quarterly basis, EBT rose 31.46% to $38.6 million in Q2 2025 year-over-year; TTM through Apr 2025 was -$17.0 million, a 70.09% increase, with the full-year FY2025 number at -$88.4 million, down 67.88% from a year prior.
  • EBT hit $38.6 million in Q2 2025 for KalVista Pharmaceuticals, up from -$44.5 million in the prior quarter.
  • Over the last five years, EBT for KALV hit a ceiling of $38.6 million in Q2 2025 and a floor of -$44.5 million in Q4 2024.
  • Historically, EBT has averaged -$14.5 million across 4 years, with a median of -$28.6 million in 2023.
  • Biggest five-year swings in EBT: plummeted 53.45% in 2024 and later soared 31.46% in 2025.
  • Tracing KALV's EBT over 4 years: stood at -$12.5 million in 2021, then tumbled by 131.39% to -$29.0 million in 2023, then plummeted by 53.45% to -$44.5 million in 2024, then skyrocketed by 186.75% to $38.6 million in 2025.
  • Business Quant data shows EBT for KALV at $38.6 million in Q2 2025, -$44.5 million in Q4 2024, and -$40.4 million in Q3 2024.